The Capital Markets team advised the initial purchasers on MannKind Corporation’s Rule 144A offering of $230 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026. The initial conversion price of the notes features a premium of approximately 30.0% up from the reference price of $4.01 per share.
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases.
Goodwin’s team consisted of Jim Barri, John Servidio, Maggie Wong, Kim Sebastian De Glossop, and Daniel Karelitz and Garrett Gaughan.
For additional information on the offering, please read the MannKind Corporation pricing press release.